Sodium oxybate for the treatment of narcolepsy

Bibliography

• OVEREEM S, MIGNOT E, VAN DIJK JG, LAMMERS GJ: Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives./ Clin. Neurophysiol. (2001) 18:78–105.
   PubMed Web of Science ®Google Scholar
• OHAYON MM, PRIEST RG, ZULLY J, SMIRNE S, PAT VA T: Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology (2002) 58:1826–1833.
   PubMed Web of Science ®Google Scholar
• SEIGEL JM: Narcolepsy: a key role for hypocretins (orexins). Cell (1999) 98:1–20.
   PubMedGoogle Scholar
• NISHINO S, RIPLEY B, OVEREEM S, LAMMERS GJ, MIGNOT E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 355:39–40.
   PubMed Web of Science ®Google Scholar
• ••The first study to demonstrate a loss ofhypocretin in the CSF of patients with narcolepsy.
   Google Scholar
• THANNICKAL TC, MOORE RY, NIEHUIS R et al: Reduced number of hypocretin neurons in human narcolepsy. Neuron (2000) 27:469–474.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of the loss ofhypocretin cells in the brains of deceased patients with narcolepsy.
   Google Scholar
• SIEGEL JM: Hypocretin (orexin): role in normal behavior and neuropathology. Ann. Rev. Psychol. (2004) 55:125–148.
   PubMed Web of Science ®Google Scholar
• HOUGHTON WC, SCAMMEL TE, THORPY M: Pharmacotherapy for cataplexy. Sleep Med. Rev. (2004) 8:355–366.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive report on thepathophysiology and treatment of cataplexy.
   Google Scholar
• HUBLIN C: Narcolepsy. Current drug treatment options. CNS Drugs (1996) 5:426–436.
   Google Scholar
• US MODAFINIL IN NARCOLEPSY MULTICENTER STUDY GROUP: Randomized trial of modafinil as a treatment for excessive daytime somnolence of narcolepsy. Neurology (2000) 54:1166–1175.
   PubMed Web of Science ®Google Scholar
• CHEN CN: The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad. Med. J. (1980) 56\(Suppl. 1):86–89.
   Google Scholar
• GUILLEMINAULT C, CARSKADON M, DEMENT WC: On the treatment of rapid eye movement narcolepsy. Arch. Neurol (1974) 30:90–93.
   PubMed Web of Science ®Google Scholar
• CHEN SY, CLIFT SJ, DAHLITZ MJ, DUNN G, PARKES JD: Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. J. Sleep Res. (1995) 4:113–118.
   PubMed Web of Science ®Google Scholar
• PARKES JD, SCHACHTER M: Clomipramine and clonazepam in cataplexy. Lancet (1979) 2:1085–1086.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-RODRIGUEZ J, IRANZO A, SANTAIVIARIA J et al.: Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia (2002) 17:113–116.
   PubMed Web of Science ®Google Scholar
• WING YK, LEE S, CHIU HF, HO CK, CHEN CN: A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine. Postgrad. Med. J. (1994) 70:34–36.
   PubMedGoogle Scholar
• SMITH M, PARKES JD, DAHLITZ M: Venlafaxine in the treatment of the narcoleptic syndrome. J. Sleep Res. (1996) 5\(Suppl. 1):217.
   Google Scholar
• LARROSA O, DE LA LLAVE Y, BARIO S, GRANIZO JJ, GARCIA-BORREGUERO D: Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep (2001) 24:282–285.
   PubMed Web of Science ®Google Scholar
• LABORIT H: Sodium 4-hydroxybutyrate. Int. J. Neuropharmacol (1964) 3:433–452.
   PubMedGoogle Scholar
• MAMELAK M, ESCRIU JM, STOKAN O: The effects of gamma-hydroxybutyrate on sleep. Biol. Psychiatry (1977) 12:273–288.
   PubMed Web of Science ®Google Scholar
• BROUGHTON R, MAMELAK M: Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can. J. Neurol Sci. (1980) 7:23–31.
   PubMed Web of Science ®Google Scholar
• SCHARF M, BROWN D, WOODS M, BROWN L, HIRSCHOWITZ J: The effects and effectiveness of -hydroxybutyrate in patients with narcolepsy. j Clin. Psych. (1985) 46:222–225.
   Web of Science ®Google Scholar
• SCRIMA L, HARTMAN PG, JOHNSON FH Jr, HILLER FC: Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol. Psychiatry (1989) 26:331–343.
   PubMed Web of Science ®Google Scholar
• SCRIMA L, HARTMAN PG, JOHNSON FH Jr, THOMAS EE, HILLER FC: The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep (1990) 13:479–490.
   PubMed Web of Science ®Google Scholar
• LAMMERS GJ, ARENDS J, DECLERCK AC, FERRARI MD, SCHOUWINK G, TROOST J: Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep (1993) 16:216–220.
   PubMed Web of Science ®Google Scholar
• •The first European double-blind study of g-hydroxybuyrate to demonstrate improvment in cataplexy and the auxiliary symptoms of narcolepsy.
   Google Scholar
• TUNNICLIFFE G: Significance of y-hydroxybutyric acid in the brain. Gen. PharmacoL (1992) 23:1027–1034.
   PubMedGoogle Scholar
• MAITRE M: The y-hydroxybutyrate signaling system in brain: organization and functional implications. Frog. NeurobioL (1997) 51:337–361.
   Google Scholar
• MADDEN TE, JOHNSON SW: Gamma-hydroxybutyrate is a GABA, receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J. PharmacoL Exp. Ther. (1998) 287:262–265.
   Google Scholar
• •Demonstration that the effect of g-hydroxybutyrate is largely through GABAB receptors.
   Google Scholar
• SCHARF MB, LAI AA, BRANIGAN B, STOVER R, BERKOWITZ DB: Pharmacokinetics of gamma-hydroxybutyrate (GHB) in narcoleptic patients. Sleep (1998) 21:507–514.
   PubMed Web of Science ®Google Scholar
• BORGEN L, LANE E, LAI A: Xyrem (sodium oxybate). A study of dose proportionality in healthy human subjects. Clin. PharmacoL (2000) 40:1053.
   Google Scholar
• BORGEN LA, OKERHOLM R, MORRISON D, LAI A: The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J. Clin. PharmacoL (2003) 43:59–65.
   PubMed Web of Science ®Google Scholar
• BORGEN LA, OKERHOLM RA, SCHARF MB: The pharmacokinetics of sodium oxybate following acute and chronic administration to narcoleptic patients. J. Clin. PharmacoL (2004) 44: 253–257.
   PubMed Web of Science ®Google Scholar
• PALATINI P, TEDESCHI L, FRISON G et al.: Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur. j Clin. PharmacoL (1993) 45:353–356.
   PubMed Web of Science ®Google Scholar
• NELSON T, KAUFMAN E, KLINE J, SOKOLOFF L: The extraneural distribution of y-hydroxybutyrate. J. Neurochem. (1981) 37:1345–1348.
   PubMedGoogle Scholar
• KAUFMAN EE, NELSON T: An overview of gamma-hydroxybutyrate catabolism: the role of the cytosolic NADP(±)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. Neurochem. Res. (1991) 16:965–974.
   Google Scholar
• US XYREM MULTICENTER STUDY GROUP: A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep (2002) 25(1):42–49.
   PubMedGoogle Scholar
• ••The first comprehensive, placebo-controlled trial of Xyrem in narcolepsy.
   Google Scholar
• US XYREM MULTICENTER STUDY GROUP: Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. (2004) 5:119–123.
   PubMed Web of Science ®Google Scholar
• US XYREM MULTICENTER STUDY GROUP: A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep (2003) 26:31–35.
   PubMed Web of Science ®Google Scholar
• MAMELAK M, BLACK J, MONTPLAISIR J, RISTANOVIC R: A dose response study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep (In Press).
   Google Scholar
• Xyrem® Product Information, Orphan Medical, Inc.
   Google Scholar
• TARABAR AF, NELSON LS: The gamma-hydroxybutyrate withdrawal syndrome. Toxicol. Rev. (2004) 23:45–49.
   PubMedGoogle Scholar
• TAKAHARA J, YUNOKI S, YAKUSHIJI W, YAMAUCHI J, YAMANE Y: Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J. Clin. EndocrinoL Metab. (1977) 44:1014–1017.
   PubMed Web of Science ®Google Scholar
• TETER CJ, GUTHRIE SK: A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy (2001) 21:1486–1513.
   PubMed Web of Science ®Google Scholar
• FOOD AND DRUG ADMINISTRATION: Gamma hydroxybutyric acid. Press release. Rockville, MD: November 8 (1990).
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Multistate outbreak of poisonings associated with illicit use of gamma hydroxybutyrate. J. Am. Med. Assoc. (1991) 256:447–448.
   Google Scholar
• DRUG ENFORCEMENT ADMINISTRATION: Schedules of controlled substances: addition of gamma hydroxybutyric acid to schedule I. Fed. Reg. (2000) 65:13235–13238.
   Google Scholar
• FULLER DE, HORNFELDT CS, KELLOWAY JS, STAHL PJ, ANDERSON TF: The Xyrem® Risk Management Program. Drug Saf (2004) 27:293–306.
   PubMed Web of Science ®Google Scholar